Erica Roper, PA
Medical · Bluffton, SCNPI 1356686141
Payments from drug & device makers
Across 167 payments — averaging $18.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$576
- Lilly USA, LLC$431
- Novo Nordisk$342
- Abbott$224
- AbbVie$204
- Amgen$147
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,056100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 29 | $576 |
| Lilly USA, LLC | 25 | $431 |
| Novo Nordisk | 22 | $342 |
| Abbott | 5 | $224 |
| AbbVie | 12 | $204 |
| Amgen | 9 | $147 |
| Boehringer Ingelheim | 8 | $147 |
| AstraZeneca | 6 | $96 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $94 |
| Biohaven Pharmaceuticals, Inc. | 4 | $82 |
| Esperion Therapeutics, Inc. | 5 | $77 |
| Novartis | 4 | $66 |
| Teva Pharmaceuticals USA, Inc. | 4 | $65 |
| GSK | 4 | $64 |
| Exact Sciences | 4 | $64 |
| Amarin Pharma, Inc. | 3 | $50 |
| Idorsia Pharmaceuticals US Inc | 3 | $47 |
| Eisai Inc. | 2 | $40 |
| Bausch Health US, LLC | 2 | $35 |
| Genentech USA, Inc. | 2 | $24 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Radius Health, Inc. | 1 | $22 |
| Bayer | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Lupin Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| Hologic Sales And Service, LLC | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| VBI Vaccine (delaware) Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INFINITY$130
How this compares
$3,056 in reported general payments places this provider in the 75th percentile of 384 medical providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 123 | $141,567 |
| MounjaroTirzepatide | 90 | $110,096 |
| EliquisApixaban | 59 | $86,381 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 41 | $53,908 |
| JardianceEmpagliflozin | 45 | $39,080 |
| TrulicityDulaglutide | 17 | $25,299 |
| MyrbetriqMirabegron | 24 | $22,056 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $21,525 |
| FarxigaDapagliflozin Propanediol | 12 | $18,046 |
| XareltoRivaroxaban | 11 | $17,217 |
| Repatha SureclickEvolocumab | 15 | $14,226 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $13,791 |
| JanuviaSitagliptin Phosphate | 19 | $13,444 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $8,778 |
| NexletolBempedoic Acid | 12 | $5,522 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $342 | $141,567123 claims |
| Lilly USA, LLCMounjaro, Trulicity | $431 | $135,395107 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance | $147 | $92,98886 claims |
| PfizerEliquis | $576 | $86,38159 claims |
| Astellas Pharma US IncMyrbetriq | $16 | $22,05624 claims |
| AstraZenecaFarxiga | $96 | $18,04612 claims |
| GSKBreo Ellipta | $64 | $8,77814 claims |
| Esperion Therapeutics, Inc.Nexletol | $77 | $5,52212 claims |
| AbbVieSynthroid | $204 | $1,74742 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 384 medical providers in South Carolina.
Other medical in Bluffton
- Christopher ThompsonSpartanburg$78K
- Laura BuchGreenville$73K
- Suzanne SmithWest Columbia$39K
- Stavros ChrysostomidesColumbia$39K
- Ethan CaseySpartanburg$24K
- Jessica HallColumbia$22K
- Mary MacdonaldCharleston$20K
- Cameron PappasGreenville$18K
- Leslie RumbautGrenville$18K
- Claire DukeGreenville$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.